About: Big pharma
EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation
The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.
Health care risks being forgotten in Brexit talks, industry warns
Health risks being forgotten in Brexit negotiations, potentially delaying the availability of new medicines and imposing large costs on manufacturers, public health leaders have warned.OpinionPromoted content
Drugs incentives have saved lives in Europe
Without strong incentives to spur continued investment in medical innovation, we cannot hope to ensure the sustainability of European healthcare systems and fulfil the promise of our great union, writes Jan Fischer.
Pharma boss: Targeting drugs won’t make healthcare systems more sustainable
“Salami-slicing” the cost of medicines, which represent almost one-fifth of health system budgets and are subject to rigorous value assessments, won’t make healthcare systems more sustainable in the future, Nathalie Moll told EURACTIV.com in an interview.
Drugs firms call for phased transition of regulation after Brexit
Pharmaceutical companies called on Thursday (27 April) for a phased transition in drug regulation after Britain leaves the European Union, in order to avoid supply disruption and protect public health.
Fake drugs cost EU billions of euros, its health and its jobs
Counterfeit drugs are not only hazardous to health, they cost people their jobs too, a new EU study has revealed. But Germans in particular are willing to take risks. EURACTIV's partner Der Tagesspiegel reports.
Don’t be fooled by CETA: It’s a wolf in sheep’s clothing
In his State of the Union speech, Jean-Claude Juncker called the Canada-EU trade agreement the most progressive trade agreement the EU has ever negotiated. It actually poses a genuine threat to the health sector, argues Emma Woodford.